MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a study finds.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Pet owners in Abu Dhabi welcomed the government's decision to require all pets to be registered on the TAMM portal, believing ...

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting thousands of patients in England. The move will also “significantly free up ...

As the weeks go by, more and more Bond 2023 projects are underway. New surveillance cameras at Odessa High School have been installed and Permian High School is near completion. New Tech Odessa will ...

The escalating global plastics crisis, exemplified by the >31 million tons of PET production in 2019, necessitates efficient recycling strategies as ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.